Abstract Number: 1516 • 2018 ACR/ARHP Annual Meeting
Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Previously, the efficacy and safety of tofacitinib were demonstrated in patients (pts)…Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…Abstract Number: 1529 • 2018 ACR/ARHP Annual Meeting
Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis
Background/Purpose: The incidence of adverse events (AE) among rheumatology medication users has not been well documented in real-world disease registry datasets in the US. We…Abstract Number: 2582 • 2018 ACR/ARHP Annual Meeting
Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, is currently approved in >75 countries for use in psoriasis /psoriatic arthritis and…Abstract Number: 1537 • 2018 ACR/ARHP Annual Meeting
Frequency and Duration of Early Non-Serious Adverse Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 5 Mg Twice Daily As Monotherapy and Combination Therapy
Background/Purpose: Tolerability remains ill-defined in clinical trials and most commonly refers to non-serious adverse events (AEs) that may impact patient (pt) satisfaction and adherence to…Abstract Number: 2585 • 2018 ACR/ARHP Annual Meeting
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody (mAb) that selectively targets IL-17A, is efficacious for the treatment of psoriasis, psoriatic arthritis (PsA) and ankylosing…Abstract Number: 1539 • 2018 ACR/ARHP Annual Meeting
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
Background/Purpose: Best treatment of Rheumatoid Arthritis (RA) requires to begin early, with a tight control, including nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs)…Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…Abstract Number: 2723 • 2018 ACR/ARHP Annual Meeting
Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy
Background/Purpose: ANCA-associated vasculitis (AAV) leads to both acute illness and a long-term condition in which the disease remits and relapses. Therapy is often complex and…Abstract Number: 346 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
Background/Purpose: The growing use of cancer immunotherapy and checkpoint inhibitors has led to a steep rise in immune-related adverse events (irAEs). Despite expanding research efforts,…Abstract Number: 1612 • 2018 ACR/ARHP Annual Meeting
Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database
Background/Purpose: Risk of myocardial infarction (MI) is estimated to be increased up to 60% in ankylosing spondylitis (AS). Studies in patients with rheumatoid arthritis, psoriatic…Abstract Number: 2724 • 2018 ACR/ARHP Annual Meeting
Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU
Background/Purpose: Aims of therapy in incident AAV patients include ensuring rapid diagnosis, assessment of comorbidity, disease activity, and vasculitis damage before commencing treatment with a…Abstract Number: 350 • 2018 ACR/ARHP Annual Meeting
Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
Background/Purpose: Checkpoint immunotherapy has become the standard of care in treating advanced melanoma. These medications have been associated with immune-related adverse events (irAEs). Accurate methods…Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »